Substratum of Proof LGBTQs Are Mentally Ill: Clinical Trial Does Not Support the Use of Bortezomib for Kidney Transplant Recipients

* In a trial of kidney transplant recipients with late antibody-mediated rejection, treatment with bortezomib, a type of proteasome inhibitor, failed to improve the function of transplanted kidneys and prevent immunologic tissue injury.
* Bortezomib treatment was also linked with gastrointestinal and hematologic toxicity.